Evidence map›Paper›PMID 34174139›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2022

Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: Incidence, risk factors, and effect on renal allograft function.

Lynn D Cornell, Hatem Amer, Jason K Viehman, Ramila A Mehta, John C Lieske, Elizabeth C Lorenz, Julie K Heimbach, Mark D Stegall, Dawn S Milliner, Rare Kidney Stone Consortium Primary Hyperoxaluria (RKSC PH) investigators

Open access · hybridAbstract read
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Diagnosis and management of primary hyperoxalurias: best practices.Pediatric nephrology (Berlin, Germany) · 2024
    Review
  6. Article
  7. Review
  8. Review
  9. SulfatedAntioxidants (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Lynn D CornellDivision of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-5091-2863
Hatem AmerDivision of Nephrology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Jason K ViehmanDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
Ramila A MehtaDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
John C LieskeDivision of Nephrology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Elizabeth C LorenzDivision of Nephrology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-1012-9409
Julie K HeimbachDivision of Transplant Surgery, William J. von Liebig Transplant Center, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-3567-1328
Mark D StegallDivision of Transplant Surgery, William J. von Liebig Transplant Center, Mayo Clinic, Rochester, Minnesota, USA.
Dawn S MillinerDivision of Nephrology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-4799-1668
Rare Kidney Stone Consortium Primary Hyperoxaluria (RKSC PH) investigators
Mayo Clinic · US

Funding

Primary HyperoxaluriaU54DK083908 · NIDDK · MAYO CLINIC ROCHESTER · PI MILLINER, DAWN SCHMAUTZ · 2009 to 2018
$12.3M
Improving frailty and long-term outcomes after kidney transplantationK23DK123313 · NIDDK · MAYO CLINIC ROCHESTER · PI LORENZ, ELIZABETH C. · 2019 to 2023
$795k
NIDDK NIH HHS K23 DK123313NIDDK NIH HHS U54 DK083908
6 · The paper itself

Abstract

Primary hyperoxaluria (PH) is a metabolic defect that results in oxalate overproduction by the liver and leads to kidney failure due to oxalate nephropathy. As oxalate tissue stores are mobilized after transplantation, the transplanted kidney is at risk of recurrent disease. We evaluated surveillance kidney transplant biopsies for recurrent calcium oxalate (CaOx) deposits in 37 kidney transplants (29 simultaneous kidney and liver [K/L] transplants and eight kidney alone [K]) in 36 PH patients and 62 comparison transplants. Median follow-up posttransplant was 9.2 years (IQR: [5.3, 15.1]). The recurrence of CaOx crystals in surveillance biopsies in PH at any time posttransplant was 46% overall (41% in K/L, 62% in K). Higher CaOx crystal index (which accounted for biopsy sample size) was associated with higher plasma and urine oxalate following transplant (p < .01 and p < .02, respectively). There was a trend toward higher graft failure among PH patients with CaOx crystals on surveillance biopsies compared with those without (HR 4.43 [0.88, 22.35], p = .07). CaOx crystal deposition is frequent in kidney transplants in PH patients. The avoidance of high plasma oxalate and reduction of CaOx crystallization may decrease the risk of recurrent oxalate nephropathy following kidney transplantation in patients with PH. This study was approved by the IRB at Mayo Clinic.

Indexed as

HyperoxaluriaHyperoxaluria, PrimaryKidney TransplantationAllograftsCalcium OxalateHumansIncidenceKidneyRisk FactorsCalcium Oxalateclinical research / practicekidney transplantation / nephrologyprotocol biopsyrecurrent disease

Identifiers

PMID34174139
PMCPMC8710184
OpenAlexW3174410699

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.